Page last updated: 2024-10-31

mitoxantrone and Clinically Isolated CNS Demyelinating Syndrome

mitoxantrone has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 3 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Doshi, A1
Chataway, J1
Jaster, JH1
Niell, HB1
Dohan, FC1
Smith, TW1
Tourbah, A1
Stievenart, JL1
Edan, G1
Abanou, A1
Dormont, D1
Lyon-Caen, O1

Reviews

1 review available for mitoxantrone and Clinically Isolated CNS Demyelinating Syndrome

ArticleYear
Multiple sclerosis, a treatable disease .
    Clinical medicine (London, England), 2017, Volume: 17, Issue:6

    Topics: Adjuvants, Immunologic; Alemtuzumab; Crotonates; Demyelinating Diseases; Dimethyl Fumarate; Fingolim

2017

Other Studies

2 other studies available for mitoxantrone and Clinically Isolated CNS Demyelinating Syndrome

ArticleYear
Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.
    Neurology, 2003, Apr-22, Volume: 60, Issue:8

    Topics: Adult; Antineoplastic Agents; Carcinoma; Cohort Studies; Colonic Neoplasms; Demyelinating Diseases;

2003
Acute demyelination: an insight into the effect of mitoxantrone on CNS lesions.
    Journal of neuroradiology = Journal de neuroradiologie, 2005, Volume: 32, Issue:1

    Topics: Acute Disease; Adult; Brain Diseases; Demyelinating Diseases; Female; Humans; Magnetic Resonance Ima

2005